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Although long-term data for relapse-free survival and
overall survival are available for many patients treated
with adjuvant chemotherapy, there are conﬂicting
results about the optimum dose intensity.1 Studies of the
relation between obesity and breast cancer have
described both an aetiological and negative prognostic
effect for increased body-mass index (BMI).2 A possible
explanation for this effect in overweight women
receiving adjuvant systemic therapy for early-stage
breast cancer is that although doses should be based on
body surface area (BSA), suboptimum doses can be
prescribed. Concerns of possible altered drug
disposition in obese patients has resulted in empiric
dose reductions (eg, reduction in the chemotherapy dose
after ﬁnal-dose calculation, or use of the ideal
bodyweight to calculate BSA) to avoid excessive toxicity.
Few data are available to lend support to these policies or
to alternative descriptors of body size (eg, lean
bodyweight). However, retrospective analyses suggest
that toxicity is not excessive in the obese cancer patient
who is fully dosed according to BSA, and that empiric
reductions for the patient with raised BMI are not only
unnecessary3 but might also result in shortened disease
free-survival.4
To assess the relation between BMI, chemotherapy
dose reduction, oestrogen receptor expression, and
outcome, we reviewed the data from four randomised
trials of the International Breast Cancer Study Group
(IBCSG: formerly the Ludwig Group) assessing adjuvant
classical CMF (cyclophosphamide, methotrexate, and 
5-ﬂuorouracil) in premenopausal women with node-
positive breast cancer. These trials were done between
1978 and 1993 in many countries, and complied with
ethics committee and informed consent requirements at
the time for all localities. No endocrine therapy (eg,
tamoxifen) was prescribed in these patients. Because
clinical evidence and consensus guidelines5 accord with
the hypothesis of differential treatment effects according
to endocrine responsiveness of the primary tumour, all
analyses were done separately for ER-negative and 
ER-positive cohorts. To reduce the risk that patient
intolerance might contribute to the results, we deﬁned
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Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We
assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary
tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide,
methotrexate, and 5-ﬂuorouracil). Obese patients were signiﬁcantly more likely to receive a lower chemotherapy dose
(85% of expected dose) for the ﬁrst course than were those with normal or intermediate BMI (39% vs 16%,
p0·0001). For obese patients and for the total population, reducing the dose of chemotherapy was associated with
a signiﬁcantly worse outcome for the ER-negative cohort (total population hazards ratio 85% vs 85% 0·68 [95%
CI 0·54–0·86] for disease free survival; 0·72 [0·56–0·94] for overall survival) but not for the ER-positive cohort (1·16
[0·97–1·40] for disease-free survival; 1·16 [0·94–1·44] for overall survival) [interaction p values=0·0001 for disease-
free survival and 0·0019 for overall survival]. Our ﬁndings suggest that for women with ER-absent or ER-low
tumours, reduction in chemotherapy dose should be avoided.
Years of accrual Eligible patients Patients with     Patients with  Patients treated Treatment group Median (range)
known BMI known ER status with 1 course (cycles) years of follow up
of CMF
Trial I 1978–81 491 380 204 204 CMF (12) 22 (6·5–25)
CMFp (12)
Trial II 1978–81 161* 116 67 66 CMFp (12) 22 (1·6–24)
Trial V 1981–85 475 475 417 406 PeCMFCMFp (6) 18 (1·6–22)
CMFp (6)
Trial VI 1986–93 1475 1472 1472 1464 CMF (6) 12 (0·4–17)
CMF (6)3 reint
CMF (3)
CMF (3)3 reint
Total 2602 2443 2160 2140
C=cyclophosphamide, 100 mg/m2 oral days 1–14 of each cycle. M=methotrexate, 40 mg/m2 intravenously , days 1 and 8 of each cycle. F=5-ﬂuorouracil, 600 mg/m2 intravenously days 1
and 8 of each cycle. P=prednisone, 7·5 mg/day oral for 6 months or 12 months. PeCMF=perioperative CMF. Reint=reintroduction of 3 cycles of CMF. *Does not include 166 patients who
were randomised to receive oophorectomy followed by CMFp12.
Table 1: IBCSG trials and treatment groups
See http://www.ibcsg.org
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dose groups (85% of the dose and 85%) for the ﬁrst
course and included only patients who received
more than one course of CMF. A total of 2140 such
patients who had known BMI and ER status were
included in the data analyses (table 1). BMI groups
were deﬁned as: normal (25 kg/m2); intermediate
(25–29·9 kg/m2); and obese (30 kg/m2). The
distribution of patients analysed in the three
categories was 60% (1279), 28% (612), 12% (249),
respectively. 
A higher proportion of obese patients (39% [97 of 249])
received less than 85% of protocol speciﬁed dose during
the ﬁrst course of CMF compared with patients with
normal and intermediate BMI (16% [298 of 1891];
p0·0001). Obese patients initially treated with
expected doses of chemotherapy (85%) did not have
more grade 3/4 toxicity than patients who received
reduced (85%) doses (14% [22 of 152] vs 12% [12 of 97]
respectively; p=0·62).
For obese patients with ER-negative disease, those who
received 85% or more of the ﬁrst course dose had
signiﬁcantly better disease-free survival (DFS) and
overall survival (OS) (table 2) than those who received
less than 85%. Dose reduction for obese patients with
ER-positive disease did not signiﬁcantly compromise
outcome (table 2). For the obese group, the interaction
term (dose-level and ER-status) in the Cox model was
signiﬁcant for both DFS (p=0·0078) and OS (p=0·0104),
indicating that the effect of dose on outcome differed
signiﬁcantly between the ER-negative and the ER-
positive cohort. 
Similar differences in the effect of dose reduction on
outcome according to ER-status were seen for
the intermediate and for the normal BMI groups
(table 2). Considering all patients together in analyses
stratiﬁed by BMI group, reduced dose in the ﬁrst
cycle compared with protocol speciﬁed dose was
associated with a signiﬁcantly worse outcome for the ER-
negative cohort but with a non-signiﬁcant better
outcome for the ER positive cohort (table 2; DFS
interaction term hazards ratio 1·77 [1·33–2·37];
p=0·0001; OS interaction 1·69 [1·21–2·34]; p=0·0019).
When the analyses were restricted to the 1563 (73%)
patients included in trials of CMF alone (without low-
dose prednisone) the size of the interaction between the
dose reduction and ER cohort was larger than for
the entire group, both overall and within BMI
subgroups (DFS interaction term hazards ratio
2·01 [1·42–2·83]; p0·0001; OS interaction 1·99
[1·34–2·95]; p=0·0007). 
N DFS OS
10-year DFS% Hazard ratio* p 10-year OS% Hazards ratio* p
(SD) (95% CI) (SD) (95% CI)
ER-negative†
BMI obese
Dose level 85% 49 49 (7) 0·55 (0·33–0·93) 0·0261 57 (7) 0·50 (0·28–0·88) 0·0158
Dose level 85% 40 28 (7) 38 (8)
BMI intermediate 
Dose level 85% 179 52 (4) 0·67 (0·43–1·03) 0·0676 62(4) 0·75 (0·46–1·22) 0·2440
Dose level 85% 41 35 (8) 52 (8)
BMI normal
Dose level 85% 368 48 (3) 0·75 (0·54–1·05) 0·0966 60 (3) 0·84 (0·57–1·24) 0·3702
Dose level 85% 62 41 (6) 58 (6)
Total stratiﬁed by BMI group
Dose level 85% 596 49 (2) 0·68 (0·54–0·86) 0·0013 60 (2) 0·72 (0·56–0·94) 0·0142
Dose level 85% 143 36 (4) 50 (4)
ER-positive†
BMI obese 
Dose level 85% 103 37 (5) 1·20 (0·80–1·81) 0·3687 59 (5) 1·26 (0.78–2.06) 0·3492
Dose level 85% 57 44 (7) 63 (6)
BMI intermediate 
Dose level 85% 335 41 (3) 1·04 (0·73–1·49) 0·8360 59 (3) 0·99 (0·65–1·49) 0·9418
Dose level 85% 57 49 (7) 59 (7)
BMI normal
Dose level 85% 711 45 (2) 1·21 (0·94–1·55) 0·1318 63 (2) 1·22 (0·91–1·62) 0·1880
Dose level 85% 138 53 (4) 71 (4)
Total stratiﬁed by BMI group
Dose level 85% 1149 43 (1) 1·16 (0·97–1·40) 0·1028 61 (1) 1·16 (0·94–1·44) 0·1707
Dose level 85% 252 50 (3) 66 (3)
*Hazard ratio= 85% dose versus 85% dose. †ER-negative=0–9 fmol/mg cytosol protein. ER-positive= 10 fmol/mg cytosol protein. DFS=disease-free survival. OS=overall survival. For
DFS, interaction p values comparing dose level effects between ER-negative and ER-positive cohorts are p=0·0078 for obese BMI group, p=0·0838 for intermediate BMI group, p=0·0273
for normal BMI group, and p=0·0001 for total group. For OS, interaction p values comparing dose level effects between ER-negative and ER-positive cohorts are p=0·0104 for obese BMI
group, p=0·2861 for intermediate BMI group, p=0·1627 for normal BMI group, and p=0·0019 for total group. 
Table 2: Disease-free survival and overall survival comparing 85% dose level versus 85% dose level according to oestrogen-receptor (ER) cohort and
body-mass index (BMI) group 
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Our ﬁndings provide substantial additional evidence
for the hypothesis that steroid hormone receptor status
of the primary tumour deﬁnes distinct biological entities
that need a differentiated approach to treatment and
clinical trial investigations. Although we cannot exclude
that dose-reduction was related to unrecorded comorbid
conditions other than obesity, this possibility is unlikely
because the patients included in our analysis all
participated in randomised clinical trials that required
documentation of adequate haematological, renal, and
hepatic function before enrolment. In a retrospective
assessment of the dose-response effect in obese patients
given adjuvant chemotherapy,4 the adjusted failure risk
ratio for obese patients who received more than 95% of
the dose compared with lower doses was 0·73. We
predict that a larger effect would be observed if the
analysis were restricted to the population with endocrine
non-responsive disease, and invite such analyses by
other groups. 
Our results indicate that for patients with endocrine
non-responsive disease (ER-absent and ER-low tumour),
a reduced dose during the ﬁrst course of chemotherapy
is detrimental. The absence of a clinically signiﬁcant
increase in the risk of grade 3/4 toxicity and the
improved outcome in terms of DFS and OS for patients
with endocrine non-responsive breast cancer who did
not have doses reduced indicate that a priori reduction in
the chemotherapy dose for these patients should be
avoided. 
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